Sam Brusco, Associate Editor10.02.23
Shoulder Innovations (SI) has hired Jeff Points as its new chief financial officer (CFO).
Points has 25 years of experience in finance and was most recently CFO of Cardiovascular Systems. He will lead all financial and IT aspects for Shoulder Innovations.
"I am delighted to be joining Rob and the terrific team at SI to help drive the continued momentum of the business," Points told the press. "SI operates in a very large, fast-growing market, and I am excited to support the robust growth of the business and help the company reach its full potential."
SI also welcomed Jon Osborne as VP of commercial development. He was most recently VP of commercial marketing at Smith+Nephew, focused on the sports medicine portfolio.
Rob Ball, CEO of Shoulder Innovations said, "I could not be more excited and flattered to have two executives of this caliber and experience join our small team. The Shoulder Innovations team has accomplished much with a lean and efficient team. Augmenting our leadership will allow us to continue to improve our ability to scale our successful business and execute our plans with precision."
SI holds a portfolio of various components for the integrated InSet shoulder arthroplasty system, which includes the InSet Glenoid, Humeral, Reverse, and Stemless configurations. The company claims InSet was shown in testing to significantly reduce glenoid implant micro-motion.
Points has 25 years of experience in finance and was most recently CFO of Cardiovascular Systems. He will lead all financial and IT aspects for Shoulder Innovations.
"I am delighted to be joining Rob and the terrific team at SI to help drive the continued momentum of the business," Points told the press. "SI operates in a very large, fast-growing market, and I am excited to support the robust growth of the business and help the company reach its full potential."
SI also welcomed Jon Osborne as VP of commercial development. He was most recently VP of commercial marketing at Smith+Nephew, focused on the sports medicine portfolio.
Rob Ball, CEO of Shoulder Innovations said, "I could not be more excited and flattered to have two executives of this caliber and experience join our small team. The Shoulder Innovations team has accomplished much with a lean and efficient team. Augmenting our leadership will allow us to continue to improve our ability to scale our successful business and execute our plans with precision."
SI holds a portfolio of various components for the integrated InSet shoulder arthroplasty system, which includes the InSet Glenoid, Humeral, Reverse, and Stemless configurations. The company claims InSet was shown in testing to significantly reduce glenoid implant micro-motion.